FDA names permanent CDER director, boosts safety office

Share this article:
The FDA selected Gerald Dal Pan as director of the Office of Drug Safety in the Center for Drug Evaluation and Research (CDER). 
Dal Pan will report directly to the head of CDER, elevating the stature of the safety office to a level on par with the Office of New Drugs, which approves new medicines for sale, an FDA spokeswoman told MM&M.
Dal Pan joined the FDA in 2000. He most recently served as director, division of surveillance, research, and communication support, Office of Drug Safety in CDER, a position he has held since 2003. 
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.